Improving Targeted Therapies for Patients with Previously Untreated Advanced Classic Hodgkin Lymphoma
Apr 8, 2018 ·
39m 59s
In this episode of The Onco'Zine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Dr. Joseph M. Connors, MD., FRCPC, Clinical Professor in the Department of Medicine, Division of...
show more
In this episode of The Onco'Zine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Dr. Joseph M. Connors, MD., FRCPC, Clinical Professor in the Department of Medicine, Division of Medical Oncology, at the University of British Columbia and the chair of the Lymphoma Tumor Group for the British Columbia Cancer Agency.
Dr. Connors is also the lead investigator of the ECHELON-1 clinical trial, a trial focusing on a new treatment option for Hodgekin Lymphoma.
In this interview Hofland and Portillo talks with Dr. Connor about some of the latest results from the ECHELON-1 clinical trial, which tests an antibody-drug conjugate or ADC called brentuximab vedotin (ADCETRIS; being developed by Seattle Genetics and Takeda), as a frontline treatment option for patients with advanced classical Hodgkin Lymphoma. They also talk with Dr. Connors about how the ECHELON-1 study was conducted, and why it is important for this patient group, and for cancer research as a whole.
show less
Dr. Connors is also the lead investigator of the ECHELON-1 clinical trial, a trial focusing on a new treatment option for Hodgekin Lymphoma.
In this interview Hofland and Portillo talks with Dr. Connor about some of the latest results from the ECHELON-1 clinical trial, which tests an antibody-drug conjugate or ADC called brentuximab vedotin (ADCETRIS; being developed by Seattle Genetics and Takeda), as a frontline treatment option for patients with advanced classical Hodgkin Lymphoma. They also talk with Dr. Connors about how the ECHELON-1 study was conducted, and why it is important for this patient group, and for cancer research as a whole.
Information
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
